Respiratory Failure

Respiratory failure is a life-threatening condition in which the lungs can no longer do their most basic job: getting enough oxygen into the blood and removing carbon dioxide from it. It is one of the most common reasons people end up in an intensive care unit, and understanding what type of respiratory failure is happening — and why — determines almost every treatment decision that follows.

Table of Contents

1. What Is Respiratory Failure?
2. Type 1: Hypoxemic Respiratory Failure
3. Type 2: Hypercapnic (Ventilatory) Respiratory Failure
4. Causes by Category: Obstructive, Restrictive, Neuromuscular, Vascular
5. How Doctors Measure Respiratory Failure: ABGs and the Alveolar-Arterial Gradient
6. Acute vs Chronic Respiratory Failure
7. Treatment: Supplemental Oxygen, Non-Invasive Ventilation, Intubation
8. Mechanical Ventilation: Modes, Settings, and Weaning
9. Long-Term Outcomes and Rehabilitation
10. Key Research Papers
11. Featured Videos

1. What Is Respiratory Failure?

The respiratory system has two jobs: deliver oxygen (O2) from the air into the bloodstream, and carry carbon dioxide (CO2) — a waste gas produced by every cell in the body — back out through the breath. Respiratory failure means the system can no longer keep up with either or both of those demands.

Doctors define respiratory failure precisely using a test called an arterial blood gas (ABG), which measures oxygen and carbon dioxide levels directly in the blood. The two defining thresholds are:

• Oxygen (PaO2) below 60 mmHg — this is hypoxemic (Type 1) respiratory failure. At normal sea-level breathing, a healthy adult typically has a PaO2 of 80–100 mmHg. Dropping below 60 is the point at which body tissues — including the heart and brain — begin to be deprived of adequate oxygen.
• Carbon dioxide (PaCO2) above 45 mmHg — this is hypercapnic (Type 2) respiratory failure. CO2 builds up when the lungs cannot expel it fast enough, making the blood acidic and interfering with every organ system.

A person can have Type 1 alone, Type 2 alone, or both simultaneously. Which type is present shapes every treatment decision, because giving too much oxygen to a patient with Type 2 failure caused by severe COPD can paradoxically make CO2 retention worse — a counterintuitive fact that catches families and even some non-specialist clinicians off guard.

Respiratory failure is extremely common. In the United States, respiratory failure and acute respiratory distress syndrome (ARDS) together account for an estimated 300,000–400,000 deaths per year, making it among the leading causes of critical illness. The survival rate has improved markedly since the 1990s thanks to lung-protective ventilation strategies, but respiratory failure remains a medical emergency demanding rapid diagnosis and treatment.

Back to Table of Contents

2. Type 1: Hypoxemic Respiratory Failure

In Type 1 respiratory failure, the blood oxygen level is dangerously low (PaO2 below 60 mmHg), but carbon dioxide may be normal or even low because the person is often breathing faster to compensate. The problem is that the lungs are failing to transfer oxygen from the air into the blood, even though the breathing muscles may be working hard.

There are five distinct mechanisms that can cause low oxygen in this way:

1. Ventilation-Perfusion (V/Q) Mismatch

This is the most common cause of hypoxemia in respiratory failure. In a healthy lung, every region that receives blood flow (perfusion) also receives airflow (ventilation) — the two are matched. In many diseases, this matching breaks down. Some lung regions receive blood but little or no air (low V/Q ratio — blood passes through without picking up oxygen), while others receive air but poor blood flow (high V/Q ratio — wasted ventilation). The net result is poorly oxygenated blood leaving the lungs. Supplemental oxygen generally helps V/Q mismatch because increasing the oxygen concentration in the inhaled air can compensate for the reduced airflow reaching some regions. Common causes include pneumonia, pulmonary embolism, ARDS, atelectasis (collapsed lung segments), and pulmonary edema.

2. Shunt

A shunt means blood travels from the right side of the heart to the left — and then out to the body — without ever passing through functioning lung tissue to pick up oxygen. This can happen inside the heart itself (intracardiac shunt, such as a patent foramen ovale or atrial septal defect) or inside the lungs (intrapulmonary shunt, where alveoli are completely flooded or collapsed so no gas exchange can occur). The key distinguishing feature of a shunt: giving the patient 100% oxygen does not significantly raise their PaO2. This is because the blood passing through the shunt bypasses the oxygenated air entirely, no matter how concentrated that air is. Recognizing a shunt is important because oxygen therapy alone will not fix it — the underlying cause (e.g., draining a massive pleural effusion, treating flooding alveoli) must be addressed.

3. Diffusion Impairment

Oxygen must cross from the air sac (alveolus) through a thin membrane into the blood capillary. When this membrane becomes thickened — as in pulmonary fibrosis, interstitial lung disease, or sarcoidosis — oxygen transfer slows. Diffusion impairment often shows up first during exercise, when blood moves through the lungs faster and has less time to equilibrate with the alveolar oxygen. At rest, there may be enough time for adequate transfer despite the thickened membrane, but any increase in demand unmasks the problem.

4. Hypoventilation

When breathing is too slow or too shallow, less fresh air reaches the alveoli each minute. This directly lowers alveolar oxygen while raising alveolar carbon dioxide. Hypoventilation therefore causes both hypoxemia and hypercapnia — making it technically a Type 2 mechanism as well. Classic causes include opioid or sedative overdose, severe obesity hypoventilation syndrome, and neuromuscular diseases that weaken the breathing muscles. The hypoxemia from pure hypoventilation corrects easily with supplemental oxygen because the problem is simply a low concentration of oxygen in the alveolar air, not a structural lung problem.

5. Low Inspired Oxygen Fraction

At high altitude, the percentage of oxygen in the air is the same (~21%) but atmospheric pressure is lower, so there are fewer oxygen molecules per breath. In enclosed or confined spaces with inadequate ventilation — including industrial accidents, grain silos, or fires consuming oxygen — the inspired oxygen fraction can fall low enough to cause acute hypoxemia in anyone, regardless of their health status.

The Alveolar-Arterial (A-a) Gradient: A Diagnostic Key

To determine which mechanism is at play, doctors calculate the alveolar-arterial (A-a) gradient — the difference between the oxygen level the alveolus is supposed to deliver (PAO2, calculated from a formula) and the oxygen level actually measured in the arterial blood (PaO2). A normal A-a gradient is roughly 10–20 mmHg in young healthy adults and rises modestly with age. If the A-a gradient is normal and the patient is hypoxemic, the cause is almost certainly hypoventilation or low inspired oxygen. If the A-a gradient is elevated, something is wrong with the lung itself — V/Q mismatch, shunt, or diffusion impairment — and further investigation is needed.

Back to Table of Contents

3. Type 2: Hypercapnic (Ventilatory) Respiratory Failure

In Type 2 respiratory failure, carbon dioxide builds up in the blood (PaCO2 above 45 mmHg) because the lungs are not moving enough air each minute to clear it. This is sometimes called ventilatory failure because the problem is with the pump — the mechanics of breathing — rather than (or in addition to) the gas exchange surface.

Why CO2 Rises

Every cell in the body continuously produces carbon dioxide as a byproduct of metabolism. CO2 diffuses from cells into the blood, is carried to the lungs, and is exhaled. The amount exhaled per minute equals the respiratory rate multiplied by the tidal volume (the size of each breath) — this is called minute ventilation. When minute ventilation falls below what is needed to clear the CO2 being produced, PaCO2 rises. This can happen because:

• Pump failure: The breathing muscles (diaphragm, intercostals, accessory muscles) cannot generate enough force to move adequate volumes of air. This is the mechanism in neuromuscular diseases, obesity hypoventilation, and chest wall deformities.
• Increased dead space: Some of the air inhaled never reaches functioning alveoli — it sits in the trachea and large airways (anatomical dead space) or reaches alveoli that have no blood flow (physiological dead space, as in massive pulmonary embolism or severe emphysema). If dead space increases substantially, a larger fraction of each breath is wasted, and effective CO2 elimination falls.

What Rising CO2 Does to the Blood

CO2 dissolves in blood to form carbonic acid (CO2 + H2O → H2CO3 → H+ + HCO3⁻). In acute hypercapnia — when CO2 rises over minutes to hours — the blood becomes acidic rapidly (pH drops below 7.35, causing respiratory acidosis). The brain and heart are particularly sensitive to acidosis; severe acute hypercapnia can cause confusion, drowsiness, seizures, arrhythmias, and cardiac arrest.

In chronic hypercapnia — when CO2 has been elevated for weeks to months, as in advanced COPD — the kidneys compensate by retaining bicarbonate (HCO3⁻). This buffers the acid and brings the pH back toward normal, a state called compensated respiratory acidosis. These patients may have PaCO2 values of 55–65 mmHg with a near-normal pH because their bicarbonate has risen proportionally.

The Oxygen Risk in COPD: Why Less Is Sometimes More

For patients with chronic hypercapnia from COPD, giving too much supplemental oxygen can worsen CO2 retention. Two mechanisms explain this:

1. The Haldane effect: Oxygenated hemoglobin binds CO2 less avidly than deoxygenated hemoglobin. When supplemental oxygen substantially raises hemoglobin saturation, CO2 is released from hemoglobin into the plasma, raising dissolved CO2 in the blood.
2. V/Q worsening: In COPD, poorly ventilated lung regions maintain some blood flow via a reflex called hypoxic pulmonary vasoconstriction — blood vessels in poorly oxygenated regions constrict, diverting blood to better-ventilated areas. High-flow oxygen abolishes this protective reflex, allowing blood to flow freely into poorly ventilated regions, worsening V/Q mismatch and effective dead space.

For this reason, the target oxygen saturation in COPD (and other causes of chronic hypercapnia) is 88–92% on pulse oximetry — not the 95–100% target used in most other conditions. Giving enough oxygen to raise SpO2 above 92% in a COPD patient risks driving up CO2 and worsening respiratory failure.

Back to Table of Contents

4. Causes by Category: Obstructive, Restrictive, Neuromuscular, Vascular

Respiratory failure is a final common pathway reached by many different diseases. Understanding the underlying category helps predict which type of failure will occur and which treatments will work.

Obstructive Causes

These involve narrowed or blocked airways that impede airflow, increasing the work of breathing and trapping air or CO2:

• COPD exacerbation — the single most common cause of acute Type 2 (hypercapnic) respiratory failure seen in emergency departments. A chest infection or other trigger inflames already-damaged airways, further obstructing airflow and exhausting the breathing muscles.
• Severe asthma (status asthmaticus) — prolonged bronchospasm that does not respond to usual bronchodilator therapy. Initially patients hyperventilate (low PaCO2), but as the attack continues and muscles fatigue, CO2 rises — a "normalizing" PaCO2 in a severe asthmatic is actually a warning sign of impending failure.
• Upper airway obstruction — anaphylaxis causing laryngeal edema, foreign body aspiration, epiglottitis (particularly in unvaccinated children or adults), or rapidly enlarging neck hematoma after surgery. These are airway emergencies requiring immediate intervention.

Restrictive Causes

These involve stiff or compressed lungs and chest walls that limit how much air can be taken in:

• Pulmonary fibrosis — progressive scarring of lung tissue stiffens the lungs, reducing lung volumes and impairing oxygen diffusion. As fibrosis advances, patients develop Type 1 failure that worsens on exertion before becoming present at rest.
• Obesity hypoventilation syndrome (OHS) — excessive weight on the chest wall reduces lung expansion, particularly during sleep. Many OHS patients have overlapping obstructive sleep apnea. Chronic CO2 retention develops over years. Weight loss and positive airway pressure therapy are the definitive treatments.
• Pleural effusion or pneumothorax — fluid or air in the pleural space compresses the underlying lung. A tension pneumothorax — where a one-way valve effect allows air to accumulate under pressure — is a rapidly fatal emergency requiring immediate needle decompression.
• Severe kyphoscoliosis — extreme spinal curvature distorts the chest wall and restricts lung expansion. In severe cases, Type 2 failure develops in adulthood and eventually requires nocturnal non-invasive ventilation.

Neuromuscular Causes

These affect the neural signals or muscle function needed to drive breathing, causing pump failure with Type 2 failure:

• Guillain-Barré syndrome (GBS) — an immune-mediated polyneuropathy that progressively paralyzes the breathing muscles. The key clinical threshold is a forced vital capacity (FVC) below 15–20 mL/kg body weight, at which point prophylactic intubation is strongly considered rather than waiting for clinical deterioration. GBS patients can deteriorate with frightening speed over hours.
• Amyotrophic lateral sclerosis (ALS) — gradual loss of both upper and lower motor neurons supplying the diaphragm and accessory muscles. Noninvasive ventilation (BiPAP) is introduced when FVC drops below 50% predicted or when symptoms of hypoventilation appear during sleep. Eventually, patients face a decision about transitioning to invasive mechanical ventilation via tracheostomy.
• Myasthenic crisis — the autoimmune attack on acetylcholine receptors at the neuromuscular junction weakens the diaphragm and bulbar muscles, causing respiratory failure. Plasma exchange or intravenous immunoglobulin (IVIG) can reverse the crisis.
• High cervical spinal cord injury — injury at C3–C4 or above paralyzes the diaphragm (phrenic nerve origin C3–C5). These patients cannot breathe independently and require immediate ventilatory support.
• Opioid overdose — opioids suppress the respiratory centers in the brainstem, reducing respiratory rate and tidal volume dramatically. This causes acute Type 2 failure that can be reversed within minutes by naloxone (Narcan), making it one of the few immediately reversible causes of respiratory arrest.
• Botulism — toxin from Clostridium botulinum blocks acetylcholine release at the neuromuscular junction, causing descending paralysis. Respiratory failure is the life-threatening complication; treatment is supportive ventilation plus antitoxin.

Vascular Causes

• Massive pulmonary embolism — a large clot obstructing the main pulmonary arteries causes acute cor pulmonale (right heart strain), massive dead space (blood cannot reach the clots to pick up or deliver gas), and ventilatory failure. Systemic thrombolysis or catheter-directed therapy may be life-saving.
• Fat embolism syndrome — bone marrow fat enters the bloodstream after long bone fractures (especially femur fractures) and lodges in the pulmonary vasculature. Presents 24–72 hours after injury with the classic triad of hypoxemia, neurological changes, and petechial rash.

Parenchymal (Lung Tissue) Causes

• Pneumonia — alveolar consolidation causes intrapulmonary shunt and V/Q mismatch. Severe pneumonia can progress to ARDS.
• ARDS — a syndrome of diffuse bilateral lung injury with massive alveolar flooding, devastating shunt physiology, and extremely stiff lungs. See the ARDS page for dedicated coverage.
• Pulmonary edema — fluid in the alveoli from heart failure (cardiogenic) or increased capillary permeability (non-cardiogenic). Cardiogenic pulmonary edema responds dramatically to diuretics and vasodilators; non-cardiogenic is treated like ARDS.
• Acute exacerbation of interstitial lung disease (ILD) — a sudden, often fatal worsening of fibrotic lung disease with a mechanism resembling ARDS superimposed on already-damaged lung.

Back to Table of Contents

5. How Doctors Measure Respiratory Failure: ABGs and the Alveolar-Arterial Gradient

The arterial blood gas (ABG) is the cornerstone test for diagnosing and classifying respiratory failure. Blood is drawn from an artery (usually the radial artery at the wrist) rather than a vein, because only arterial blood reflects what the lungs have actually delivered to the body.

The ABG Numbers and Their Meanings

• pH (normal: 7.35–7.45) — measures acidity. Below 7.35 = acidosis; above 7.45 = alkalosis. The pH tells you whether the overall balance is off.
• PaCO2 (normal: 35–45 mmHg) — the partial pressure of CO2 in arterial blood. High CO2 (hypercapnia) drives respiratory acidosis. Low CO2 (hypocapnia) drives respiratory alkalosis (e.g., hyperventilation from anxiety or sepsis).
• PaO2 (normal: 80–100 mmHg on room air) — the partial pressure of oxygen in arterial blood. Below 60 mmHg defines hypoxemic (Type 1) failure.
• HCO3⁻ (bicarbonate; normal: 22–26 mEq/L) — the kidneys' buffer. High bicarbonate compensates for chronic CO2 retention; low bicarbonate compensates for metabolic acidosis.
• SpO2 — the pulse oximeter reading showing the percentage of hemoglobin carrying oxygen. Convenient and continuous but can be falsely reassuring in carbon monoxide poisoning (where CO-hemoglobin reads as normal) and in severe anemia (oxygen content is low even if saturation appears normal).

A Step-by-Step ABG Approach

1. Is there hypoxemia? PaO2 below 60 → yes.
2. What is the primary acid-base disturbance? pH below 7.35 = acidosis; pH above 7.45 = alkalosis.
3. Is the primary disturbance respiratory (abnormal PaCO2) or metabolic (abnormal HCO3⁻)?
4. Is there appropriate compensation? (Respiratory acidosis: kidneys retain HCO3⁻. Metabolic acidosis: lungs increase respiratory rate to blow off CO2.)
5. Calculate the A-a gradient to determine whether a lung problem is present.

The P/F Ratio: Grading Hypoxemia Severity

The P/F ratio (PaO2 divided by the fraction of inspired oxygen, or FiO2) standardizes the hypoxemia measurement regardless of how much supplemental oxygen is being given. A patient on room air breathes an FiO2 of 0.21 (21% oxygen).

• P/F above 400: normal gas exchange
• P/F 300–400: mild impairment
• P/F below 300: mild ARDS criteria met
• P/F below 200: moderate ARDS
• P/F below 100: severe ARDS

Example: a patient with a PaO2 of 80 on room air has a P/F of 80 ÷ 0.21 = 381 (normal). A patient with a PaO2 of 60 while on 100% oxygen (FiO2 = 1.0) has a P/F of only 60 — indicating catastrophic shunting where the lung is barely transferring oxygen even on maximum inspired concentration.

Back to Table of Contents

6. Acute vs Chronic Respiratory Failure

The speed of onset matters enormously in respiratory failure because the body's ability to compensate takes time — and the absence of compensation means acute failure can be immediately fatal even at CO2 levels that a patient with chronic disease tolerates indefinitely.

Acute Respiratory Failure

Develops over minutes to hours. The kidneys have had no time to compensate, so the ABG shows frank acidosis (pH below 7.35 with elevated PaCO2 in Type 2, or low PaO2 in Type 1). Common causes include acute pulmonary embolism, sudden-onset asthma, acute pneumonia, opioid overdose, and aspiration. These are emergencies requiring immediate intervention — supplemental oxygen, non-invasive ventilation, or intubation depending on severity.

Chronic Respiratory Failure

Develops over weeks to months. The kidneys have had time to retain bicarbonate, bringing the pH back near normal — a state called compensated respiratory acidosis. Patients with advanced COPD, obesity hypoventilation syndrome, and slowly progressive neuromuscular diseases may have PaCO2 values of 55–70 mmHg with a pH of 7.36–7.40 and markedly elevated bicarbonate (32–40 mEq/L). These patients have adapted to their elevated CO2 and may feel relatively well at their baseline.

Acute-on-Chronic: The Most Dangerous Pattern

This occurs when a patient with established chronic respiratory failure experiences an additional acute insult — typically a respiratory infection. The baseline PaCO2 is already elevated. When an acute exacerbation pushes CO2 higher, the kidneys cannot compensate fast enough, and the pH drops acutely below the compensated range. These patients are critically ill. The ABG shows high PaCO2, elevated bicarbonate (from chronic compensation), but pH falling below 7.30 or even lower — a combination that tells the clinician this is a crisis superimposed on a chronic disease. Acute-on-chronic Type 2 failure in COPD patients is one of the most common ICU presentations and is where non-invasive ventilation (BiPAP) has demonstrated the greatest life-saving benefit.

Back to Table of Contents

7. Treatment: Supplemental Oxygen, Non-Invasive Ventilation, Intubation

Treatment is matched to the mechanism and severity of respiratory failure. The hierarchy moves from the least invasive to the most invasive intervention, advancing if lower-level support is insufficient.

Supplemental Oxygen Delivery

Corrects hypoxemia in Type 1 failure from V/Q mismatch, hypoventilation, or low inspired oxygen. Does not correct shunt-dominated hypoxemia or CO2 retention.

• Nasal cannula (1–6 L/min): delivers approximately 24–44% FiO2. Comfortable and well-tolerated. Adequate for mild hypoxemia.
• Simple face mask (6–10 L/min): approximately 40–60% FiO2. Minimum 6 L/min to wash out exhaled CO2 from the mask.
• Non-rebreather mask (10–15 L/min with reservoir bag): can deliver 70–90% FiO2. Suitable for moderate-to-severe hypoxemia while awaiting definitive airway management.
• Heliox (helium-oxygen mixtures, typically 70:30 or 80:20): helium is less dense than nitrogen, reducing the turbulence of airflow through narrowed airways. Used as a bridge in severe upper airway obstruction and acute severe asthma. Not widely available but can buy time while bronchodilators and systemic steroids take effect.

High-Flow Nasal Cannula (HFNC)

High-flow nasal cannula devices (such as Optiflow) can deliver heated, humidified air-oxygen mixtures at flow rates up to 60 L/min through wide-bore nasal prongs. Because the flow rate exceeds the patient's peak inspiratory demand, the inspired gas is nearly 100% of what is delivered — so FiO2 can be set precisely from 21% to 100%. At high flows, HFNC also generates a small amount of positive end-expiratory pressure (PEEP) in the nasopharynx — roughly 1–5 cmH2O — which helps keep some alveoli open.

The FLORALI trial (2015, NEJM) showed that HFNC reduced intubation rates compared to standard oxygen therapy and conventional non-invasive ventilation in patients with acute hypoxemic (Type 1) respiratory failure. HFNC is now widely used as a first-line intervention for Type 1 failure — but its evidence base for Type 2 (hypercapnic) failure is much weaker, and it should not replace BiPAP for COPD exacerbations with CO2 retention.

Non-Invasive Ventilation (NIV): BiPAP and CPAP

NIV delivers positive pressure through a tight-fitting face mask or nasal mask, without placing a tube in the airway. It is one of the most evidence-backed interventions in respiratory medicine.

BiPAP (bilevel positive airway pressure) delivers a higher pressure during inhalation (IPAP — inspiratory positive airway pressure, typically 12–20 cmH2O) and a lower pressure during exhalation (EPAP — typically 4–8 cmH2O). This combination assists each breath, reduces the work of breathing, and improves CO2 elimination. In the landmark Brochard 1995 NEJM trial, BiPAP reduced the intubation rate by approximately 50% and mortality significantly in COPD exacerbation patients with acute hypercapnia. NIV is now a Class I (highest evidence) recommendation for COPD exacerbation with Type 2 failure.

CPAP (continuous positive airway pressure) delivers a constant pressure throughout the breathing cycle (typically 5–10 cmH2O). It splints open the alveoli, recruits collapsed units, and reduces the fluid transudation from edematous capillaries in cardiogenic pulmonary edema. CPAP dramatically reduces the need for intubation in acute cardiogenic pulmonary edema.

Contraindications to NIV — situations where the airway must be secured with intubation instead: inability to protect the airway (swallowing dysfunction, altered consciousness), active vomiting, excessive secretions, facial trauma or burns preventing mask fit, hemodynamic instability, and respiratory arrest.

Intubation and Mechanical Ventilation

When non-invasive approaches are insufficient, a tube must be placed through the mouth into the trachea (orotracheal intubation) or through a surgical opening in the neck (tracheostomy) to protect the airway and connect the patient to a mechanical ventilator.

Rapid sequence intubation (RSI) is the standard technique: the patient is given a sedative agent (etomidate or ketamine are commonly used) followed immediately by a rapid-onset neuromuscular blocking agent (succinylcholine for a fast and brief block, or rocuronium at high dose for a longer block). This induces apnea within 60 seconds, allowing the clinician to place the tube quickly while minimizing the risk of aspiration.

Preoxygenation before intubation is critical: 3–5 minutes of 100% oxygen by mask fills the lungs with an oxygen reservoir that extends the safe apnea time during laryngoscopy. A supplementary technique is apneic oxygenation — leaving a nasal cannula running at 15 L/min even during laryngoscopy; passive diffusion of oxygen into the non-breathing lungs can extend safe apnea time by several additional minutes.

Video laryngoscopy (using a camera-equipped blade to visualize the cords on a screen) has become standard in most ICUs, as it provides a superior view compared to traditional direct laryngoscopy, particularly in patients with limited neck mobility or difficult anatomy.

Back to Table of Contents

8. Mechanical Ventilation: Modes, Settings, and Weaning

A mechanical ventilator takes over the work of breathing by pushing air (or an air-oxygen mixture) into the lungs with each breath. The science of how to do this optimally — especially for patients with damaged lungs — has advanced enormously since the 1990s.

Volume-Controlled Ventilation

In volume-controlled assist-control (AC/VC) mode, the clinician sets a fixed tidal volume (the amount of air delivered with each breath), a backup respiratory rate, the FiO2, and the PEEP (positive end-expiratory pressure — the pressure maintained in the airways at the end of exhalation, which keeps alveoli from collapsing). The ventilator delivers exactly the set volume whether the patient triggers a breath or not. The resulting airway pressure varies depending on lung stiffness (compliance).

Pressure-Controlled Ventilation

In pressure-controlled mode, the clinician sets a target inspiratory pressure rather than a volume. The ventilator delivers breaths until that pressure is reached; the resulting tidal volume depends on how stiff the lungs are. If the lungs become more compliant (easier to inflate), the delivered volume increases; if they stiffen, volume falls. Close monitoring of tidal volumes is essential in PC mode.

Lung-Protective Ventilation for ARDS

The most important paradigm shift in mechanical ventilation over the past 30 years is lung-protective ventilation, driven by the ARDSnet trial published in 2000. The key finding: in ARDS, ventilating with traditional tidal volumes (10–12 mL/kg body weight) overdistended the surviving healthy alveoli, causing additional injury (volutrauma and barotrauma). Reducing tidal volumes to 6 mL/kg of ideal body weight (IBW — based on height, not actual weight) reduced absolute mortality by 9 percentage points and became the standard of care.

Additional lung-protective parameters:

• Plateau pressure below 30 cmH2O — plateau pressure (measured during a brief pause in airflow) reflects the pressure actually reaching the alveoli. Keeping it below 30 cmH2O limits alveolar overdistension.
• PEEP titrated to FiO2 — the PEEP-FiO2 tables from the ARDSnet trial provide a starting point: as more oxygen support is needed, PEEP is incrementally increased to recruit more alveoli and reduce FiO2 dependence.
• Permissive hypercapnia — using low tidal volumes often means CO2 rises above normal (since less air is moved per minute). This is acceptable — PaCO2 values of 50–60 mmHg with pH of 7.25–7.35 are tolerated in ARDS to avoid the harm of higher tidal volumes. Exceptions: raised intracranial pressure (where CO2 elevation is dangerous) and severe pulmonary hypertension.

Prone Positioning

Turning a ventilated ARDS patient onto their stomach (prone position) redistributes lung blood flow, recruits collapsed posterior alveoli, and homogenizes ventilation-perfusion matching. The PROSEVA trial (2013, NEJM) showed that 16 hours per day of prone positioning in severe ARDS (P/F below 150, FiO2 above 60%) reduced 28-day mortality from 32.8% to 16% — one of the most striking survival benefits ever demonstrated in critical care. Prone positioning is now standard of care for severe ARDS.

Neuromuscular Blockade

In early severe ARDS, continuous infusion of a neuromuscular blocking agent (typically cisatracurium) eliminates patient-ventilator dyssynchrony (fighting the ventilator with spontaneous breaths out of phase with machine breaths) and reduces oxygen consumption by the breathing muscles. The ACURASYS trial (2010, NEJM) suggested improved 90-day mortality with early paralysis, though the larger ROSE trial (2019) did not replicate this benefit in a setting where light sedation was used in the control group. Current practice generally reserves neuromuscular blockade for severe dyssynchrony or refractory hypoxemia.

Weaning from Mechanical Ventilation

Weaning — the process of reducing ventilatory support until the patient can breathe independently — is as important as initiating ventilation. Premature extubation (removing the tube too early) leads to reintubation, which is associated with significantly higher mortality. Prolonged ventilation causes its own harms: ventilator-associated pneumonia, deconditioning, pressure injuries, and psychological trauma.

Daily spontaneous breathing trials (SBTs) are the cornerstone of weaning. Once the patient's condition is improving, they are placed on minimal ventilatory support — either a T-piece (breathing ambient air through the tube with no machine assistance) or low pressure support ventilation (PSV 5 cmH2O over 5 cmH2O PEEP) — for 30–120 minutes. If they tolerate this without distress, deteriorating oxygen levels, or hemodynamic instability, extubation is planned.

The rapid shallow breathing index (RSBI), developed by Yang and Tobin in their landmark 1991 NEJM paper, predicts SBT success: RSBI = respiratory rate divided by tidal volume (in liters). An RSBI below 105 breaths/min/L predicts successful extubation; above 105 predicts failure. It remains the most validated weaning predictor in clinical use.

The ABCDE bundle — Awakening (daily sedation holidays), Breathing (daily SBTs), Coordination (of awakening + breathing trials), Delirium screening and management, and Early mobility — is the evidence-based framework for optimizing weaning and minimizing ICU complications.

Tracheostomy

For patients who need more than 10–14 days of mechanical ventilation, a tracheostomy (a surgically placed tube directly through the front of the neck into the trachea) offers several advantages: reduced work of breathing (shorter, lower-resistance airway), ability to speak with a speaking valve, easier oral feeding trials, better patient comfort, and potentially faster weaning. The TracMan trial (2013, JAMA) found no mortality difference between early (within 4 days) and late (after 10 days) tracheostomy, suggesting there is no urgency to perform it early — but it remains an important option for prolonged ventilation.

Back to Table of Contents

9. Long-Term Outcomes and Rehabilitation

Surviving respiratory failure — especially requiring mechanical ventilation — is only the beginning of recovery. The ICU creates its own burden of injury that can persist for years.

ICU-Acquired Weakness

Between 25% and 50% of patients who spend more than a week on mechanical ventilation develop ICU-acquired weakness — a combination of critical illness polyneuropathy (damage to peripheral nerves from systemic inflammation) and critical illness myopathy (muscle wasting from immobility, corticosteroids, and neuromuscular blocking agents). Patients may leave the ICU unable to walk, lift their arms, or swallow. Recovery can take months to years, and some patients never fully regain baseline strength.

Post-Intensive Care Syndrome (PICS)

PICS encompasses the constellation of cognitive, psychological, and physical impairments that follow an ICU admission. Cognitive deficits (memory problems, difficulty concentrating, executive dysfunction) affect 30–80% of ICU survivors at 3 months; psychological problems including post-traumatic stress disorder, depression, and anxiety are common in both survivors and their family members. Physical weakness and fatigue are nearly universal early in recovery. PICS is now recognized as a public health problem in its own right, distinct from the underlying disease that caused the ICU admission.

The Herridge 2011 NEJM study followed ARDS survivors for 5 years after hospital discharge and found persistent functional disability: reduced exercise capacity, neuropsychological impairment, and reduced health-related quality of life — even in patients who appeared to have physically recovered. These findings transformed how the field thinks about the long-term burden of critical illness.

Pulmonary Rehabilitation

Pulmonary rehabilitation is a formally structured program combining supervised exercise training, education about lung disease self-management, and psychosocial support. For patients with COPD, pulmonary fibrosis, or post-ARDS lung injury, pulmonary rehabilitation is one of the most effective interventions available — improving exercise tolerance, reducing breathlessness, and improving quality of life, even when it cannot improve the underlying lung function measurements. It is recommended by guidelines for all patients with COPD who remain symptomatic despite optimal medical therapy, and increasingly for post-ICU survivors.

Home Ventilation

Patients with chronic neuromuscular respiratory failure (ALS, GBS recovery, high cervical spinal cord injury, severe OHS) may be discharged home on noninvasive ventilation (nocturnal BiPAP) or, in the case of complete ventilator dependence, on home mechanical ventilation via tracheostomy. Home ventilator programs, when well-supported, allow patients to live in their communities rather than long-term care facilities.

Back to Table of Contents

10. Key Research Papers

1. Brochard L, Mancebo J, Wysocki M, et al. Noninvasive ventilation for acute exacerbations of chronic obstructive pulmonary disease. N Engl J Med. 1995;333(13):817–822. PMID: 7651472. DOI: 10.1056/NEJM199509283331301. Landmark RCT demonstrating that BiPAP reduced intubation rate by ~50% and in-hospital mortality in COPD exacerbations — the trial that established NIV as the standard of care.
2. Acute Respiratory Distress Syndrome Network. Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. N Engl J Med. 2000;342(18):1301–1308. PMID: 10793162. DOI: 10.1056/NEJM200005043421801. The ARDSnet trial establishing 6 mL/kg IBW tidal volume as the standard for lung-protective ventilation, reducing absolute mortality by 9%.
3. Guerin C, Reignier J, Richard JC, et al. Prone positioning in severe acute respiratory distress syndrome. N Engl J Med. 2013;368(23):2159–2168. PMID: 23688302. DOI: 10.1056/NEJMoa1214103. PROSEVA trial: 16 hours/day of prone positioning in severe ARDS halved 28-day mortality from 32.8% to 16.0%.
4. Frat JP, Thille AW, Mercat A, et al. High-flow oxygen through nasal cannula in acute hypoxemic respiratory failure. N Engl J Med. 2015;372(23):2185–2196. PMID: 25981908. DOI: 10.1056/NEJMoa1503326. FLORALI trial demonstrating HFNC superiority over standard oxygen and conventional NIV in reducing intubation rates in non-hypercapnic acute respiratory failure.
5. Papazian L, Forel JM, Gacouin A, et al. Neuromuscular blockers in early acute respiratory distress syndrome. N Engl J Med. 2010;363(12):1107–1116. PMID: 20843245. DOI: 10.1056/NEJMoa1005372. ACURASYS trial showing improved 90-day survival with early cisatracurium infusion in severe ARDS.
6. Herridge MS, Tansey CM, Matte A, et al. Functional disability 5 years after acute respiratory distress syndrome. N Engl J Med. 2011;364(14):1293–1304. PMID: 21470008. DOI: 10.1056/NEJMoa1011802. Five-year follow-up of ARDS survivors showing persistent exercise limitation, neuropsychological deficits, and reduced quality of life — the study that defined Post-ICU Syndrome.
7. Burns KE, Meade MO, Premji A, Adhikari NK. Noninvasive positive-pressure ventilation as a weaning strategy for intubated adults with respiratory failure. Cochrane Database Syst Rev. 2013;(12):CD004127. PMID: 24347267. DOI: 10.1002/14651858.CD004127.pub3. Cochrane systematic review supporting the use of NIV as a bridge strategy during weaning from invasive ventilation.
8. Esteban A, Alia I, Gordo F, et al. Extubation outcome after spontaneous breathing trials with T-tube or pressure support ventilation. The Spanish Lung Failure Collaborative Group. Am J Respir Crit Care Med. 1997;156(2 Pt 1):459–465. PMID: 9279224. DOI: 10.1164/ajrccm.156.2.9610109. Major trial comparing weaning methods, showing equivalence of T-piece and pressure-support spontaneous breathing trials and informing current practice.
9. Yang KL, Tobin MJ. A prospective study of indexes predicting the outcome of trials of weaning from mechanical ventilation. N Engl J Med. 1991;324(21):1445–1450. PMID: 2023603. DOI: 10.1056/NEJM199105233242101. Landmark study establishing the rapid shallow breathing index (RSBI <105) as the most validated predictor of successful extubation.
10. Nava S, Hill N. Non-invasive ventilation in acute respiratory failure. Lancet. 2009;374(9685):250–259. PMID: 19616722. DOI: 10.1016/S0140-6736(09)60496-7. Comprehensive review of the evidence base for NIV across all major indications in acute respiratory failure, including COPD, cardiogenic pulmonary edema, and pneumonia.
11. Young D, Harrison DA, Cuthbertson BH, Rowan K; TracMan Collaborators. Effect of early vs late tracheostomy placement on survival in patients receiving mechanical ventilation: the TracMan randomized trial. JAMA. 2013;309(20):2121–2129. PMID: 23695482. DOI: 10.1001/jama.2013.5154. TracMan trial showing no mortality advantage to early tracheostomy, informing current guidance to individualize timing.
12. Ambrosino N, Venturelli E, Vagheggini G, Clini E. Rehabilitation, weaning and physical therapy strategies in chronic critically ill patients. Eur Respir J. 2012;39(2):487–492. PMID: 21835904. DOI: 10.1183/09031936.00094411. Evidence-based framework for rehabilitation and weaning strategies in patients with prolonged mechanical ventilation and ICU-acquired weakness.

PubMed Topic Searches

1. Respiratory failure mechanical ventilation
2. Non-invasive ventilation COPD exacerbation
3. Acute hypoxemic respiratory failure treatment
4. Prone positioning ARDS
5. Weaning mechanical ventilation ICU

Back to Table of Contents

11. Featured Videos

Connections

• Acute Respiratory Distress Syndrome (ARDS)
• COPD
• Pneumonia
• Pulmonary Edema
• Obstructive Sleep Apnea
• Pulmonary Fibrosis
• Pulmonary Embolism
• Carbon Monoxide Poisoning
• Alpha-1-Antitrypsin Deficiency
• Pulmonology — all topics

Back to Table of Contents